MedPath

SPECT Fibroblast Activation Protein Imaging in Patients With Cardiac Disease

Not yet recruiting
Conditions
Myocardial Fibrosis
Interventions
Diagnostic Test: 99mTc-FAPI SPECT imaging
Registration Number
NCT06326970
Lead Sponsor
Henan Institute of Cardiovascular Epidemiology
Brief Summary

This observational study aims to learn about the preliminary exploration of 99mTc-FAPI imaging in heart diseases and its potential application.

Participant involves patients with myocarditis, pulmonary hypertension, arrhythmia, myocardial infarction, dilated cardiomyopathy, and cardiac tumors, health conditions may also studied as control.

The main questions it aims to answer are 1, radionuclide 99mTc labeled fibroblast-activated protein inhibitors (99mTc-FAPI) imaging in the use of cardiac diseases and its limitations. 2, the performance in subjects with different control of hypertension to evaluate myocardial injury and fibrosis for providing a molecular biological basis for the study of diseases and mechanisms.

Participants will undergo 99mTc-FAPI imaging by Single-photon emission computed tomography (SPECT) and record their cardiac disease characterization and treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Clinical diagnosis or suspected of cardiac injury
  • Must be able to receive PET/CT scan
Exclusion Criteria
  • Pregnant women
  • Severe claustrophobia

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
99mTc-FAPI imaging in heart diseases99mTc-FAPI SPECT imagingParticipant involves patients with myocarditis, hypertension, arrhythmia, myocardial infarction, dilated cardiomyopathy, and cardiac tumors.
Primary Outcome Measures
NameTimeMethod
positive uptake3 months

99mTc-FAPI accumulation on the heart, measure the standardized uptake values (SUV)

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath